Drug
Opicapone clinical trials
Also written BIA 9-1067 and Ongentys.
- studies test it
- 42
- open now
- 0
- in phase 3
- 4
- first study started
- 2007
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
42 studies that test it; most in 2009 (10)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 10 |
| 2010 | 3 |
| 2011 | 5 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 31
- Phase 2
- 1
- Phase 3
- 4
- Phase 4
- 5
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 39 · Other 3
Bial - Portela C S.A. (37) · University Hospital of Ferrara (1) · SK Chemicals Co., Ltd. (1) · Rabin Medical Center (1) · Neurocrine Biosciences (1) · Medical University of South Carolina (1)
Often tested with
Tested in the same studies.
Levodopa (4) · Carbidopa (3) · Rasagiline (2) · Benserazide, levodopa drug combination (1) · Repaglinide (1)
Studies
Open first, then newest update. How each study uses opicapone is read from its arms, and is right about nine times in ten.
Testing it · 42
- OpiCapone Effect on Motor Fluctuations and pAiNCompletedPhase 4Bial - Portela C S.A.NCT04986982Written as Opicapone 50 mg
- OpicApone Sleep dISorderCompletedPhase 4Bial - Portela C S.A.NCT04986995Written as Opicapone
- eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedPhase 4Bial - Portela C S.A.NCT04990284Written as Opicapone
- Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT02305277Written as BIA 9-1067 (clinical micronized, CM)
- Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedPhase 3Bial - Portela C S.A.NCT04978597Written as Opicapone 50 mg
- Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's DiseaseCompletedNot applicableUniversity Hospital of FerraraNCT06432309Written as Opicapone 50 mg
- AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine TherapyTerminatedPhase 1Medical University of South CarolinaNCT03092635Written as OPC
- A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PDCompletedPhase 4SK Chemicals Co., Ltd.NCT04821687Written as Ongentys 50mg
- Relative Bioavailability and Bioequivalence of OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03820037Written as Ongentys
- Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialCompletedPhase 3Rabin Medical CenterNCT01851850Written as Opicapone
- Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedPhase 1Bial - Portela C S.A.NCT04265027Written as 50 mg BIA 9 1067
- A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.CompletedPhase 1Neurocrine BiosciencesNCT03496870Written as Opicapone
- Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03116295Written as Opicapone (OPC)
- Efficacy and Safety of Opicapone in Clinical PracticeCompletedPhase 4Bial - Portela C S.A.NCT02847442Written as BIA 9-1067
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedPhase 1Bial - Portela C S.A.NCT03119194Written as [14C]-BIA 9-1067
- Effect of Food on OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03116308Written as Opicapone (OPC)
- The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02170376Written as BIA 9-1067
- Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Bial - Portela C S.A.NCT01520987Written as BIA 9-1067
- Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067CompletedPhase 1Bial - Portela C S.A.NCT02071810Written as BIA 9-1067
- Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02169414Written as BIA 9-1067 5 mg
See all 42 studies that test opicapone →
Given in every arm · 3 — opicapone is usual care beside what is tested
- Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedPhase 2Bial - Portela C S.A.NCT01568047Written as BIA 9-1067
- Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT02305017Written as BIA 9-1067
- Effect of Opicapone at Steady State on Warfarin PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02305030Written as BIA 9-1067
Codes
What other systems call opicapone · ClinicalTrials.gg INT005622
- MeSH (NLM) C549349opicaponeConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y5929UIJ5NOPICAPONEConfirmed FDA, NLM, Wikidata
- RxNorm 2362167One source FDA
- Wikidata Q27088208opicaponeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170258OpicaponeOne source FDA
- DrugBank DB11632One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549349 | opicapone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y5929UIJ5N | OPICAPONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2362167 | — | One source FDA |
| Wikidata | Q27088208 | opicapone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170258 | Opicapone | One source FDA |
| DrugBank | DB11632 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.